Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Update

Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 31,298 shares, a decline of 36.0% from the August 31st total of 48,911 shares. Based on an average daily volume of 12,048 shares, the short-interest ratio is presently 2.6 days. Approximately 1.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright raised their price objective on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Intensity Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.00.

Get Intensity Therapeutics alerts:

View Our Latest Stock Report on Intensity Therapeutics

Intensity Therapeutics Stock Up 4.7%

INTS stock opened at $3.36 on Friday. Intensity Therapeutics has a twelve month low of $3.21 and a twelve month high of $43.50. The company has a market cap of $10.95 million, a PE ratio of -0.94 and a beta of 2.81. The business’s 50-day simple moving average is $4.13 and its 200 day simple moving average is $4.61. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, research analysts anticipate that Intensity Therapeutics will post -2.64 earnings per share for the current year.

Intensity Therapeutics Company Profile

(Get Free Report)

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.

See Also

• Five stocks we like better than Intensity Therapeutics
• Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
• Why Concentra’s Quiet Healthcare Business Keeps Winning
• Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
• Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight

Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.